ILCA warmly thanks all Partners and Sponsors for their unrestricted support to the 2015 Annual Conference and their commitment to help advance liver cancer science.
Bayer is committed to delivering science for a better life by advancing a portfolio of innovative treatments. Bayer’s oncology franchise now includes more than three oncology products and several other compounds in various stages of clinical development. Together, these products reflect the company’s approach to research, which prioritizes targets and pathways with the potential to impact the way that cancer is treated.
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
Sirtex Medical is actively engaged in the field of liver-directed therapies for cancer patients.
Our innovative technology, SIR-Spheres® microspheres (Yttrium-90 resin beads), was approved in 2002 for use in the treatment of a variety of unresectable liver tumours a well as in hepatocellular carcinoma within the European Union under a CE Mark. SIR-Spheres® microspheres are presently used at more than 250 institutions in Europe.
®SIR-Spheres is a Registered Trademark of Sirtex SIR-Spheres Pty Ltd
Celsion is a fully-integrated oncology company focused on developing a portfolio of innovative cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies. The Company’s lead program is ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, currently in Phase III development for the treatment of primary liver cancer and in Phase II development for the treatment of RCW breast cancer. The pipeline also includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian and brain cancers. Celsion has three platform technologies for the development of novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies, including TheraPlas™, TheraSilence™ and RAST ™.
A phase 3, randomized, double-blind study of tivantinib (ARQ 197) in subjects with MET-High, Child-Pugh A, ECOG 0-1, inoperable, measurable hepatocellular carcinoma (HCC) who progressed or were intolerant to one prior systemic therapy including sorafenib.
Humedics specializes in real-time liver function measurement. The Berlin based company has an innovative breath test, LiMAx, measuring liver function instantly at the bedside and identify underlying hepatic functional impairment. LiMAx provides doctors a better and safer basis in their decision making and has already successfully helped thousands of patients.